Blincyto™ (blinatumomab) – Expanded orphan indication
March 29, 2018 - The FDA announced the approval of Amgen’s Blincyto (blinatumomab) for the treatment of B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1% in adults and children.
Top